Try it, Dry it, Love it banner.

The VABYSMO Journey

 

4 Years, Over 100 Countries, More than 10 Million Doses1,2

 

Celebrate this milestone, turn up the volume!
 

 

 

nAMD

 

 



 

Fast Drying

 

 

VABYSMO showed faster drying with fewer injections* vs. aflibercept 2.0 mg3,4

Line graph of YOSEMITE and RHINE pooled analysis. Vabysmo achieved faster absence of DME with fewer injections compared to aflibercept.
Line graph of YOSEMITE and RHINE pooled analysis. Vabysmo achieved faster absence of DME with fewer injections compared to aflibercept.



 

 

Sustained Drying

 

 

Early CST improvements were maintained through Year 4, including patients switched to VABYSMO6

Bar graph of YOSEMITE and RHINE pooled analysis. Proportion of patients achieving absence of DME increased after switching from aflibercept to Vabysmo.
Bar graph of YOSEMITE and RHINE pooled analysis. Proportion of patients achieving absence of DME increased after switching from aflibercept to Vabysmo.

 

 

 

 

Strong Drying

 

 

VABYSMO showed greater* drying vs. aflibercept 2.0 mg in the matched dose phase†3

Line graph of YOSEMITE and RHINE pooled analysis. Vabysmo achieved greater CST reductions from baseline compared to aflibercept in the matched dose phase.
Line graph of YOSEMITE and RHINE pooled analysis. Vabysmo achieved greater CST reductions from baseline compared to aflibercept in the matched dose phase.

 

 

 

DME

 

 

 

 

 

 

Fast Drying

 

 

VABYSMO showed faster drying with fewer injections vs. aflibercept 2.0 mg7

Line graph of YOSEMITE and RHINE pooled analysis. Vabysmo achieved faster absence of DME with fewer injections compared to aflibercept.
Line graph of YOSEMITE and RHINE pooled analysis. Vabysmo achieved faster absence of DME with fewer injections compared to aflibercept.

 

 

 

 

Sustained Drying

 

 

~95% of patients achieved absence of DME* at end of Year 4, including patients switched to VABYSMO7

Bar graph of YOSEMITE and RHINE pooled analysis. Proportion of patients achieving absence of DME increased after switching from aflibercept to Vabysmo.
Bar graph of YOSEMITE and RHINE pooled analysis. Proportion of patients achieving absence of DME increased after switching from aflibercept to Vabysmo.

 

 

 

 

Strong Drying

 

 

VABYSMO showed greater* drying vs. aflibercept 2.0 mg in the matched dose phase†9

Line graph of YOSEMITE and RHINE pooled analysis. Vabysmo achieved greater CST reductions from baseline compared to aflibercept in the matched dose phase.

 

 

Line graph of YOSEMITE and RHINE pooled analysis. Vabysmo achieved greater CST reductions from baseline compared to aflibercept in the matched dose phase.


 

Hear From the Experts
 

 

 

Dr. Salvatore Di Lauro,

Hospital Clínico Universitario de Valladolid, Spain
 

 

Flag of Spain.

 


“The results are so good that patients themselves ask for it.”

 

 

 

 

Dr Harit Bhatt,

University Retina, US
 

 

Flag of the United States.

 


“VABYSMO’s ability to rapidly dry the retina is truly impressive. I’ve witnessed its impact on patients with nAMD, DME and RVO* in my own clinic, making it my preferred treatment option.”

 

 

 

 

Prof. Laurent Kodjikian,

University of Lyon, France
 

 

Flag of France.

 


“What impresses me most with VABYSMO is both how fast-acting and effective it is. In nearly all my patients with nAMD, DME and RVO*, whether treatment-naive or refractory, we see a rapid fluid reduction and strong visual outcomes.”

 

 

 

 

Prof. Dr Arne Viestenz,

University of Halle, Germany
 

 

Flag of Germany.

 


“I love VABYSMO because it works quickly and allows my patients to receive long treatment intervals. This increases their satisfaction and quality of life.”

 

 

 

 

Dr. Shaheer Aboobaker,

Toronto Retina Institute, Canada
 

 

Flag of Canada.


 

“Dual-inhibition with VABYSMO is proving itself to be a strong contender as a first-line agent in nAMD, DME and RVO*.”

 

 

*Macular edema secondary to RVO.

 

 

BCVA, best corrected visual acuity; CST, central subfield thickness; DME, diabetic macular edema; HR, hazard ratio; ILM, inner limiting membrane; ILM-BM, inner limiting membrane-Bruch’s membrane; IRF, intraretinal fluid; LLD, low-luminance deficit; nAMD, neovascular age-related macular degeneration; OLE, open-label extension; Ph3, Phase 3; Q4W, every 4 weeks; Q8W, every 8 weeks; Q16W, every 16 weeks; Q20W, every 20 weeks; RPE, retinal pigment epithelium; RVO, retinal vein occlusion; SmPC, summary of product characteristics; SRF, subretinal fluid; T&E, treat and extend; US, United States.

 

 

References:
 

1. Leng T, et al. Presented at Real-World Data Ophthalmology Summit  2025.

2. Vabysmo (faricimab) SmPC. Roche Registration GmbH; 2022.

3. Cheung CMG, et al. Ophthalmology. 2025;132:519–26.

4. Chaudhary V, et al. Presented at ARVO 2023.

5. Khanani AM, et al. Ophthalmology. 2024;131:914–26.

6. Sheth V, et al. Presented at EURETINA 2025.

7. Sheth V, et al. Presented at ASRS 2025.

8. Wong TY, et al. Ophthalmol. 2024;131:708–23.

9. Lim JI, et al. Ophthalmol. Retina. 2025;9:655–66.

 

 

References:

1. Leng T, et al. Presented at Real-World Data Ophthalmology Summit  2025.

2. Vabysmo (faricimab) SmPC. Roche Registration GmbH; 2022.

3. Cheung CMG, et al. Ophthalmology. 2025;132:519–26.

4. Chaudhary V, et al. Presented at ARVO 2023.

5. Khanani AM, et al. Ophthalmology. 2024;131:914–26.

6. Sheth V, et al. Presented at EURETINA 2025.

7. Sheth V, et al. Presented at ASRS 2025.

8. Wong TY, et al. Ophthalmol. 2024;131:708–23.

9. Lim JI, et al. Ophthalmol. Retina. 2025;9:655–66.